Optimizing the Use of Cangrelor in the Real World

Arman Qamar; Deepak L. Bhatt

Disclosures

Am J Cardiovasc Drugs. 2017;17(1):5-16. 

In This Article

Conclusion

Taken together, cangrelor reduces the risk of ischemic events across the full spectrum of PCI patients, with significant benefits in all major patient subsets. Cangrelor, with an attractive pharmacologic profile and beneficial effect, will play a major role in optimizing periprocedural thrombotic risk in patients treated with PCI. Future studies are needed to determine a role of cangrelor as upstream therapy in STEMI and NSTE-ACS, and as a bridge to cardiac and non-cardiac surgeries. Potential applications in other areas such as ischemic stroke also merit exploration.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....